세계의 탈모 치료제 시장 보고서 : 약제 유형, 적응증, 성별, 투여 경로, 유통 채널, 지역별(2024-2032년)

The global alopecia treatment market size reached US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.8 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032. The market is driven by the increasing prevalence of alopecia, significant investment in healthcare expenditure, and the growing aesthetic consciousness among consumers highlighting the importance of appearance and self-care.

Alopecia Treatment Market Analysis:

Major Market Drivers: The growing need for efficient treatment alternatives is due to the rise in healthcare costs and the rising prevalence of alopecia, including alopecia areata and hereditary hair loss.

Key Market Trends: The alopecia treatment market growth is driven by the growing aesthetic consciousness, influenced by social media and ideal beauty standards, and increasing awareness about alopecia conditions is encouraging people to seek medical assistance for hair loss treatment.

Geographical Trends: The alopecia treatment market forecasts indicate a substantial increase, especially in nations like the US, where growing healthcare spending fuels market expansion. Urban communities and younger people are increasing the demand for alopecia treatments owing to increased cosmetic concerns.

Competitive Landscape: Some of the major alopecia treatment companies include Aclaris Therapeutics Inc., Cellmid Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, HCell Inc., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Taisho Pharmaceutical Holdings Co. Ltd, Teva Pharmaceutical Industries Ltd., among many others.

Challenges and Opportunities: The challenges consist of the exorbitant expenses linked to specific treatments, restricted insurance coverage, and possible adverse reactions to specific interventions. The alopecia treatment market recent opportunities include technical developments that offer efficient and minimally invasive treatments and the expansion of market reach through focused marketing and awareness efforts.

Alopecia Treatment Market Trends:

Increasing Prevalence of Alopecia

Androgenetic alopecia is a prevalent form of patterned hair loss that is seen in men and women. As per the Journal of the American Academy of Dermatology International (JAAD) published survey in 2023, alopecia affects different racial and gender groups differently, 15% of postmenopausal women and over 50% of elderly males experience it, while thinning hair can begin as early as puberty. Besides this, one of the main factors driving the alopecia treatment market forward is the rising prevalence of alopecia, which includes inherited hair loss and disorders like alopecia areata. The National Alopecia Areata Foundation estimates that 6.7 million Americans and about 160 million individuals worldwide have alopecia areata or may acquire it. Currently, alopecia areata affects about 700,000 persons in the United States. Furthermore, alopecia areata affects about 2% of people worldwide, underscoring the disorder's widespread prevalence that causes hair loss. As per the alopecia treatment market overview, demand in the industry is rising as more individuals become aware and look for efficient treatment solutions. Therefore, people are resorting to medical aid for hair restoration due to advances in medical technology and a wide range of treatment options accessible, leading to a considerable expansion in the market for alopecia therapy.

Rising Healthcare Expenditure

The escalating healthcare expenditure worldwide is a pivotal factor driving the growth trajectory of the alopecia treatment market. Global healthcare spending increased by 21% on average in 2020. This number has increased even further by 2021, when it was a startling 25% higher than in 2019. Moreover, the per capita health spending increased in most peer countries between 2021 and 2022. A moderate 2.9% growth in per capita health spending was reported in the US, Australia (2.4%), Canada (0.7%), and the UK (0.5%). Among the countries for whom data was available, Belgium experienced the largest growth in per capita health spending, rising 9.6% between 2021 and 2022. Notably, developed nations show an especially notable increase in healthcare spending, indicating the willingness of individuals to spend money on cutting-edge medical treatments, such as alopecia treatments. Hence, the growing financial capacity and increased disposable income, allow more people to afford alopecia treatments, thus contributing to the market growth.

Growing Aesthetic Consciousness

Furthermore, the growing emphasis on physical appearance and aesthetic consciousness among individuals globally is significantly contributing to the expansion of the alopecia treatment market. A survey conducted by the International Society of Hair Restoration Surgery (ISHRS) revealed that ISHRS members treated on average 165 surgical patients and 396 non-surgical patients. Moreover, ISHRS members performed surgical procedures between 0-199 hair restoration in 2021 by around two-thirds (65%) of ISHRS members, with an average member performing 179 procedures, while 78% of ISHRS members performed 0-19 hair restoration surgical operations. Members completed an average of 14 hair restoration surgical procedures per month in 2021. As a result, this rising figure illustrates increased self-consciousness among individuals about their appearance, which is exacerbated by social media's effect and the representation of ideal beauty standards. The need to adhere to perceived aesthetic ideals and cultural pressures has resulted in a noteworthy demand for effective hair restoration options. Consequently, the market for alopecia treatments is growing as more people look for ways to improve their physical appearance and deal with their hair loss issues.

Alopecia Treatment Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug type, indication, gender, route of administration, and distribution channel.

Breakup by Drug Type:

Minoxidil

Finasteride

Others

Minoxidil accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug type. This includes minoxidil, finasteride, and others. According to the report, minoxidil represented the largest segment.

Minoxidil is a commonly used medication that effectively treats alopecia in many forms. Minoxidil is a popular and easily accessible therapy option for male and female pattern hair loss. It is available over the counter in many locations. This FDA-approved drug comes in several forms, including foams and topical treatments. It slows down hair loss, stimulates hair growth, and increases blood supply to hair follicles. It is widely adopted due to its relative affordability when compared to prescription drugs and its efficacy in encouraging hair growth. For instance, as per a study by Research Gate, patients were treated with low-dose oral minoxidil (LDOM) for at least 3 months as a treatment for any type of alopecia, which offers a good safety profile to treat hair loss without any life-threatening adverse effects. Thus, the increasing number of alopecia is resulting in the adoption of minoxidil to treat alopecia, positively generating alopecia treatment market revenue.

Breakup by Indication:

Androgenic Alopecia

Alopecia Areata

Alopecia Totalis

Others

Androgenic alopecia holds the largest share of the industry

A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes androgenic alopecia, alopecia areata, alopecia totalis, and others. According to the report, androgenic alopecia accounted for the largest market share.

Androgenic alopecia, commonly known as male or female pattern baldness, holds the largest segment in the market. It is primarily due to the high prevalence of androgenic alopecia globally, which affects a significant portion of men and women. Additionally, the rising awareness and acceptance of treatment options, coupled with advances in therapeutic techniques such as topical treatments, oral medications, and hair transplant procedures, have further propelled the market growth. Hence key players are introducing advanced product variants to meet these needs. For instance, in February 2024, Pelage Pharmaceuticals, a clinical-stage regenerative medicine company created a novel treatment for hair loss, while announcing the completion of $16.75 million Series A fundraising. The funding will assist the development of a first-in-class treatment for androgenetic alopecia (pattern baldness) and other kinds of alopecia, including chemotherapy-induced hair loss. GV is leading the investment, which is also supported by Main Street Advisors, Visionary Ventures, and YK BioVentures. As a result, the increasing focus on aesthetic appearance and the psychological impact of hair loss has led to the rising demand for effective treatment solutions, solidifying androgenic alopecia's position in the alopecia treatment market outlook.

Breakup by Gender:

Male

Female

Female represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on gender. This includes male and female. According to the report, females represented the largest segment.

The growing prevalence of alopecia in females coupled with a growing awareness and acceptance of medical treatments for hair loss are influencing the market growth. Women are seeking effective solutions for alopecia due to aesthetic concerns and the psychological impact of hair loss, leading to a significant demand for pharmaceutical and cosmetic treatments. Additionally, the expansion of product offerings specifically designed for female alopecia, including topical solutions, oral medications, and advanced therapies such as platelet-rich plasma (PRP) and low-level laser therapy (LLLT), has further propelled the growth of this segment. As per the American Academy of Dermatology (AAD) association, minoxidil is recognized as an over-the-counter medication approved by the US Food and Drug Administration (FDA) for treating female pattern hair loss (FPHL), since FPHL can be treated with medications that include 2% or 5% minoxidil. Therefore, the growing focus on female-centric marketing strategies and the rising trend of self-care and wellness among women are also contributing to the expansion of alopecia treatment market.

Breakup by Route of Administration:

Oral

Topical

Injectable

Topical exhibits a clear dominance in the market

A detailed breakup and analysis of the market based on the route of administration have also been provided in the report. This includes oral, topical, and injectable. According to the report, topical accounted for the largest market share.

Topical segment holds the largest share, as it is widely used and accepted owing to its ease of use. Topical therapies, including minoxidil and corticosteroids, are non-invasive, can be administered directly to the afflicted area, and have fewer systemic adverse effects than oral and injectable options, and are frequently the first line of defense against hair loss. This route of administration is attributed to its popularity among patients who want quick fixes that work well without requiring physician care. According to the Cleveland Clinic, corticosteroids and other anti-inflammatory medications can be used to treat alopecia. It is rubbed topically (into the skin) as an ointment, cream, or foam, or injected into the scalp or other regions for the treatment.

Breakup by Distribution Channel:

Hospitals

Retail Pharmacies

Online Pharmacies

Hospitals dominate the market

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospitals, retail pharmacies, and online pharmacies. According to the report, hospitals represented the largest segment.

Hospital dominance is attributed to the extensive infrastructure and specialized medical expertise available in hospital settings, which ensure comprehensive diagnosis and tailored treatment plans for alopecia patients. Hospitals often provide a range of therapeutic options, including prescription medications, advanced medical procedures, and supportive care, making them a preferred choice for individuals seeking professional and effective alopecia management. Hence, the trust and reliability associated with hospital care contribute to their leading position in the alopecia treatment market.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest alopecia treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for alopecia treatment.

The North America alopecia treatment market recent developments are marked by the robust healthcare infrastructure, increasing prevalence of alopecia, and increased awareness about available treatment options. The presence of major pharmaceutical companies and advancements in medical technology further bolster the market in this region. For instance, in June 2023, the U.S. Food and Drug Administration (FDA) announced the approval of ritlecitinib, a Janus kinase (JAK) inhibitor by Yale dermatologist Dr. Brett King, who worked with pharmaceutical company Pfizer for conducting a series of clinical trials with ritlecitinib. It is for the treatment of alopecia areata in adolescents and adults which is an oral medication under the name Litfulo. Furthermore, the growing inclination toward aesthetic procedures and a higher disposable income enable consumers to spend on treatments for hair loss, which is positively increasing the alopecia treatment demand in North America.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the alopecia treatment industry include Aclaris Therapeutics Inc., Cellmid Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, HCell Inc., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Taisho Pharmaceutical Holdings Co. Ltd, Teva Pharmaceutical Industries Ltd., etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The key players in the global market are actively engaged in several strategic initiatives to maintain their competitive edge. They are heavily investing in research and development to introduce innovative treatments and therapies that offer enhanced efficacy and fewer side effects. Additionally, these players are focusing on expanding their global presence by entering emerging markets and capitalizing on the growing demand for hair loss solutions. Collaborations and partnerships with dermatological clinics and healthcare providers are becoming increasingly common to ensure a wider distribution network. Moreover, several companies are leveraging digital marketing and e-commerce platforms to promote their products and reach a broader consumer base, emphasizing convenience and accessibility. For instance, on 6 March 2023, Sun Pharmaceutical Industries Limited along with its subsidiaries and/or associated companies, known as Sun Pharma announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc. Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company developing deuruxolitinib, a novel deuterated oral JAK1/2 inhibitor, for the potential treatment of adult patients with moderate to severe alopecia areata.

Alopecia Treatment Market News:

5 December 2023: Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for immuno-inflammatory diseases, announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc., now Sun Pharma. Aclaris has granted Sun Pharma exclusive rights to certain patents for the use of deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, for the treatment of alopecia areata (AA) and androgenetic alopecia (AGA). It includes an upfront payment of $15 million, and regulatory and commercial milestones, and royalties. Aclaris licenses the patents exclusively from a third party and is obligated to share a portion of the consideration received from Sun Pharma due to separate contractual commitments.

14 May 2024: REVIAN Inc., a medical technology company specializing in the use of precise wavelengths of LED light for hair and skin rejuvenation, announced its participation in the 2024 Society for Investigative Dermatology Annual Meeting, scheduled in Dallas. During the event, Dr. Jacob Kocher presented a poster detailing data that demonstrates Revian's patented combination of wavelengths reduces Dihydrotestosterone (DHT) production by 74%, significantly outperforming the industry standard finasteride, which achieved a 38% reduction in DHT at 24 hours post-treatment in the same in vitro experiment. DHT is known to play a crucial role in the development of pattern hair loss androgenic alopecia or pattern baldness.

Key Questions Answered in This Report

• 1. What was the size of the global alopecia treatment market in 2023?
• 2. What is the expected growth rate of the global alopecia treatment market during 2024-2032?
• 3. What are the key factors driving the global alopecia treatment market?
• 4. What has been the impact of COVID-19 on the global alopecia treatment market?
• 5. What is the breakup of the global alopecia treatment market based on the drug type?
• 6. What is the breakup of the global alopecia treatment market based on the indication?
• 7. What is the breakup of the global alopecia treatment market based on gender?
• 8. What is the breakup of the global alopecia treatment market based on the route of administration?
• 9. What is the breakup of the global alopecia treatment market based on the distribution channel?
• 10. What are the key regions in the global alopecia treatment market?
• 11. Who are the key players/companies in the global alopecia treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Alopecia Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Type

• 6.1 Minoxidil
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Finasteride
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Indication

• 7.1 Androgenic Alopecia
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Alopecia Areata
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Alopecia Totalis
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Gender

• 8.1 Male
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Female
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

• 9.1 Oral
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Topical
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Injectable
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Distribution Channel

• 10.1 Hospitals
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Retail Pharmacies
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Online Pharmacies
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Aclaris Therapeutics Inc.
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
  • 16.3.2 Cellmid Limited
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
  • 16.3.3 Cipla Limited
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 Financials
    • 16.3.3.4 SWOT Analysis
  • 16.3.4 Dr. Reddy's Laboratories Ltd.
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 GlaxoSmithKline plc
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 HCell Inc.
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
  • 16.3.7 Johnson & Johnson
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 Merck & Co. Inc.
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
    • 16.3.8.4 SWOT Analysis
  • 16.3.9 Pfizer Inc.
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
    • 16.3.9.4 SWOT Analysis
  • 16.3.10 Taisho Pharmaceutical Holdings Co. Ltd
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials
  • 16.3.11 Teva Pharmaceutical Industries Ltd.
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
    • 16.3.11.3 Financials
    • 16.3.11.4 SWOT Analysis